


**Product Name** : JBI-589  
**Cat. No.** : PC-49339  
**CAS No.** : 2308504-22-3  
**Molecular Formula** : C<sub>29</sub>H<sub>28</sub>FN<sub>5</sub>O  
**Molecular Weight** : 481.575  
**Target** : Protein Arginine Deiminase (PAD)  
**Solubility** : 10 mM in DMSO



1. Deng H, et al. *Cancer Res.* 2022 Oct 4;82(19):3561-3572.

## Biological Activity

JBI-589 (JBI589) is potent, selective, orally active **PAD4** small molecule inhibitor, reduces CXCR2 expression and blocks neutrophil chemotaxis.

In vitro, JBI-589 inhibited PMA-induced citrullination of histone H3 in mouse neutrophils in a dose-dependent manner. JBI-589 demonstrated excellent oral bioavailability with maximum concentration in plasma achieved 0.5h after oral administration and halflife of 6.3h.

JBI-589 significantly and specifically downregulated CXCR2 expression on neutrophil, and reduced their CXCL1-induced migration.

JBI-589 treatment markedly reduced primary tumor growth LL2-bearing and B16F10-bearing mice, also improved the effect of immune checkpoint blockade (ICB).

## References

